Scinovex
article Open AccessTop 1% cited

How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)

European Heart Journal · 2019 · Vol. 40(40) · pp. 3297–3317
Burkert PieskeCarsten TschöpeRudolf A. de BoerAlan G. FraserStefan D. AnkerErwan DonalFrank EdelmannMichael FuMarco GuazziCarolyn S.P. LamPatrizio LancellottiVojtěch MelenovskýDaniel A. MorrisEike NagelElisabeth Pieske‐KraigherPiotr PonikowskiScott D. SolomonRamachandran S. VasanFrans H. RuttenAdriaan A. VoorsFrank RuschitzkaWalter J. PaulusPetar SeferovićGerasimos Filippatos

Abstract

Making a firm diagnosis of chronic heart failure with preserved ejection fraction (HFpEF) remains a challenge. We recommend a new stepwise diagnostic process, the 'HFA-PEFF diagnostic algorithm'. Step 1 (P=Pre-test assessment) is typically performed in the ambulatory setting and includes assessment for HF symptoms and signs, typical clinical demographics (obesity, hypertension, diabetes mellitus, elderly, atrial fibrillation), and diagnostic laboratory tests, electrocardiogram, and echocardiography. In the absence of overt non-cardiac causes of breathlessness, HFpEF can be suspected if there is a normal left ventricular ejection fraction, no significant heart valve disease or cardiac ischaemia, and at least one typical risk factor. Elevated natriuretic peptides support, but normal levels do not exclude a diagnosis of HFpEF. The second step (E: Echocardiography and Natriuretic Peptide Score) requires comprehensive echocardiography and is typically performed by a cardiologist. Measures include mitral annular early diastolic velocity (e'), left ventricular (LV) filling pressure estimated using E/e', left atrial volume index, LV mass index, LV relative wall thickness, tricuspid regurgitation velocity, LV global longitudinal systolic strain, and serum natriuretic peptide levels. Major (2 points) and Minor (1 point) criteria were defined from these measures. A score ≥5 points implies definite HFpEF; ≤1 point makes HFpEF unlikely. An intermediate score (2-4 points) implies diagnostic uncertainty, in which case Step 3 (F1: Functional testing) is recommended with echocardiographic or invasive haemodynamic exercise stress tests. Step 4 (F2: Final aetiology) is recommended to establish a possible specific cause of HFpEF or alternative explanations. Further research is needed for a better classification of HFpEF.

Cardiovascular Function and Risk FactorsCardiac Structural Anomalies and RepairHeart Failure Treatment and ManagementMedicineCardiologyInternal medicineHeart failureEjection fractionHeart failure with preserved ejection fractionAtrial fibrillationDiastoleBlood pressure

MeSH terms

Clinical Decision-MakingAgedAlgorithmsCardiologyEchocardiographyFemaleHeart VentriclesHumansMaleMiddle AgedPractice Guidelines as TopicConsensusNatriuretic PeptidesHeart Failure, Diastolic

Funding

  • Amgen
  • Bristol-Myers Squibb
  • Pfizer
  • AstraZeneca
  • Bayer
  • Sanofi
  • Boston Scientific Corporation
  • MyoKardia
  • Singulex
  • ResMed
  • Impulse Dynamics
  • European Commission
  • Bayer HealthCare
  • Daiichi-Sankyo
  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek
  • Novo Nordisk
  • Universitair Medisch Centrum Groningen
  • Vifor Pharma
  • Servier
  • Sphingotec GmbH
  • Abbott Vascular
  • Abbott Diagnostics
  • Medical Research Council
  • National Medical Research Council
Citations
1,712
FWCI
118.65
field-weighted impact
References
329
Percentile
100%
vs. same field & year
Citations per year
Cited by
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure
Journal of the American College of Cardiology · 2022 · 2,381 citations
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
European Respiratory Journal · 2022 · 1,919 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.